Iron chelators and antioxidants regenerate neuritic tree and nigrostriatal fibers of MPP+/MPTP-Lesioned dopaminergic neurons

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Aguirre, Pabla ^a,b   Mena, Natalia P ^a   Carrasco, Carlos M ^a,b   Muñoz, Yorka ^a,b   Pérez Henríquez, Patricio ^a   Morales, Rodrigo A ^a   Cassels, Bruce K ^a   Méndez Gálvez, Carolina ^a   García Beltrán, Olimpo ^a,c   González Billault, Christian ^a,b   Núñez, Marco T ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b Research Ring on Oxidative Stress in the Nervous System   (Chile)

^c UNIVERSIDAD DE IBAGUÉ   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,2' BIPYRIDINE; 7 DIMETHYLAMINOMETHYL 8 HYDROXYQUINOLINE; 7 MORPHOLINYLMETHYL 8 HYDROXYQUINOLINE; ACETYLCYSTEINE; ANTIOXIDANT; CELL PROTEIN; CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; DIMETHYLTHIOUREA; IRON CHELATING AGENT; M30 IRON CHELATOR; PROTEIN GIRK2; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ6 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT; PYRIDONE DERIVATIVE; QUINOLINOL DERIVATIVE; SYP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MESENCEPHALON; MOUSE; NERVE CELL CULTURE; NERVE FIBER; NERVE FIBER REGENERATION; NEURITIC TREE; NIGRONEOSTRIATAL SYSTEM; NIGROSTRIATAL FIBER; NONHUMAN; PRESYNAPTIC NERVE; RAT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; METABOLISM; MPTP POISONING; NEURITE; PATHOLOGY; PRIMARY CELL CULTURE; SPRAGUE DAWLEY RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 2,2'-DIPYRIDYL; ANIMALS; ANTIOXIDANTS; DEFEROXAMINE; DOPAMINERGIC NEURONS; FEMALE; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HYDROXYQUINOLINES; IRON CHELATING AGENTS; LIPID PEROXIDATION; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MPTP POISONING; NERVE FIBERS; NEURITES; NEUROPROTECTIVE AGENTS; PRIMARY CELL CULTURE; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; SYNAPTOPHYSIN; TYROSINE 3-MONOOXYGENASE;

EID: 84957112191     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144848     Document Type: Article

References (51)

1. Andersen HH, Johnsen KB, Moos T. Iron deposits in the chronically inflamed central nervous system and contributes to neurodegeneration. Cell Mol Life Sci. 2013. Epub 2013/11/13. doi: 10.1007/s00018-013-1509-8 .
2. Kruer MC. The neuropathology of neurodegeneration with brain iron accumulation. Int Rev Neurobiol. 2013; 110:165-94. Epub 2013/11/12. doi: 10.1016/B978-0-12-410502-7.00009-0 B978-0-12-410502-7.00009-0 [pii]. .
3. Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem. 1994; 63(3):793-807. Epub 1994/09/01. .
4. Kurian MA, Hayflick SJ. Pantothenate kinase-Associated neurodegeneration (PKAN) and PLA2G6-Associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes. Int Rev Neurobiol. 2013; 110:49-71. Epub 2013/11/12. doi: 10.1016/B978-0-12-410502-7.00003-X B978-0-12-410502-7.00003-X [pii]. .
5. Schneider SA, Bhatia KP. Excess iron harms the brain: The syndromes of neurodegeneration with brain iron accumulation (NBIA). J Neural Transm. 2013; 120(4):695-703. Epub 2012/12/06. doi: 10.1007/s00702-012-0922-8 .
6. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: A histochemical and neurochemical study. Brain Res. 1994; 660(1):8-18. .
7. Temlett JA, Landsberg JP, Watt F, Grime GW. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem. 1994; 62(1):134-46. .
8. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2007; 21 (14):3835-44. Epub 2007/08/11. doi: fj.07-8386com [pii] doi: 10.1096/fj.07-8386com .
9. Crichton RR, Dexter DT, Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm. 2011; 118(3):301-14. Epub 2010/09/03. doi: 10.1007/s00702-010-0470-z .
10. Oshiro S, Morioka MS, Kikuchi M. Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci. 2011; 2011:378278. Epub 2011/10/21. doi: 10.1155/2011/378278
11. Ward RJ, Dexter DT, Crichton RR. Chelating agents for neurodegenerative diseases. Curr Med Chem. 2012; 19(17):2760-72. Epub 2012/04/12. doi: CDT-EPUB-20120206-004 [pii]. .
12. Weinreb O, Mandel S, Youdim MB, Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med. 2013; 62:52-64. Epub 2013/02/05. doi: 10.1016/j.freeradbiomed.2013.01.017 S0891-5849(13)00027-0 [pii]. .
13. Tardiff DF, Tucci ML, Caldwell KA, Caldwell GA, Lindquist S. Different 8-hydroxyquinolines protect models of TDP-43 protein, alpha-synuclein, and polyglutamine proteotoxicity through distinct mechanisms. J Biol Chem. 2012; 287(6):4107-20. Epub 2011/12/08. doi: 10.1074/jbc.M111.308668 M111.308668 [pii].
14. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics. 2008; 5(3):421-32. doi: 10.1016/j.nurt.2008.05.001
15. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, et al. PBT2 rapidly improves cognition in Alzheimer's Disease: Additional phase II analyses. J Alzheimers Dis. 2010; 20(2):509-16. doi: 10.3233/JAD-2010-1390 .
16. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal. 2014; 21(2):195-210. doi: 10. 1089/ars.2013.5593
17. Gulledge AT, Kampa BM, Stuart GJ. Synaptic integration in dendritic trees. J Neurobiol. 2005; 64 (1):75-90. Epub 2005/05/11. doi: 10.1002/neu.20144 .
18. Vetter P, Roth A, Hausser M. Propagation of action potentials in dendrites depends on dendritic morphology. J Neurophysiol. 2001; 85(2):926-37. Epub 2001/02/13. .
19. Baloyannis SJ, Costa V, Baloyannis IS. Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. J Neurol Sci. 2006; 248(1-2):35-41. Epub 2006/06/07. doi: S0022-510X (06)00197-3 [pii] doi: 10.1016/j.jns.2006.05.006 .
20. Capetillo-Zarate E, Staufenbiel M, Abramowski D, Haass C, Escher A, Stadelmann C, et al. Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. Brain. 2006; 129(Pt 11):2992-3005. Epub 2006/07/18. doi: Awl176 [pii] doi: 10.1093/brain/awl176 .
21. Kulkarni VA, Firestein BL. The dendritic tree and brain disorders. Mol Cell Neurosci. 2012; 50(1):10-20. Epub 2012/04/03. doi: doi: 10.1016/j.mcn.2012.03.005 S1044-7431(12)00045-0
22. McNeill TH, Brown SA, Rafols JA, Shoulson I. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res. 1988; 455(1):148-52. Epub 1988/07/05. doi: 0006-8993(88)90124-2 [pii]. .
23. Solis O, Limon DI, Flores-Hernandez J, Flores G. Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson's disease. Synapse. 2007; 61(6):450-8. Epub 2007/03/21. doi: 10.1002/syn.20381 .
24. Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience. 2005; 132(3):741-54. Epub 2005/04/20. doi: S0306-4522(05)00109-0 [pii] doi: 10.1016/j.neuroscience.2005.01.007 .
25. Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ. Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology. 2006; 66(10):1591-3. Epub 2006/05/24. doi: 66/10/1591 [pii] doi: 10.1212/01.wnl.0000216137.09685.c1 .
26. Gomez FJ, Aguirre P, Gonzalez-Billault C, Nunez MT. Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+). J Neural Transm. 2011; 118(3):421-31. Epub 2010/10/05. doi: 10.1007/s00702-010-0489-1 .
27. Brouard A, Pelaprat D, Dana C, Vial M, Lhiaubet AM, Rostene W. Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors. J Neurosci. 1992; 12(4):1409-15. Epub 1992/04/01. .
28. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A. 2008; 105(47):18578-83. Epub 2008/11/18. doi: 10.1073/pnas. 08043731050804373105 [pii].
29. Beurrier C, Ben-Ari Y, Hammond C. Preservation of the direct and indirect pathways in an in vitro preparation of the mouse basal ganglia. Neuroscience. 2006; 140(1):77-86. Epub 2006/04/04. doi: S0306-4522(06)00195-3 [pii] doi: 10.1016/j.neuroscience.2006.02.029
30. Gal S, Zheng H, Fridkin M, Youdim MB. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res. 2010; 17(1):15-27. Epub 2009/07/18. doi: 10.1007/s12640-009-9070-9 .
31. Valtorta F, Pennuto M, Bonanomi D, Benfenati F. Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis? Bioessays. 2004; 26(4):445-53. Epub 2004/04/02. doi: 10.1002/bies.20012 .
32. Cobb CA, Cole MP. Oxidative and nitrative stress in neurodegeneration. Neurobiol Dis. 2015. doi: 10. 1016/j.nbd.2015.04.020 .
33. Rothblat DS, Schroeder JA, Schneider JS. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: potential contributors to spontaneous recovery from experimental Parkinsonism. J Neurosci Res. 2001; 65(3):254-66. .
34. Xu Z, Cawthon D, McCastlain KA, SlikkerWJr., Ali SF. Selective alterations of gene expression in mice induced by MPTP. Synapse. 2005; 55(1):45-51. doi: 10.1002/syn.20089 .
35. Hung HC, Lee EH. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. Brain Res Mol Brain Res. 1996; 41(1-2):14-26. .
36. Bowenkamp KE, David D, Lapchak PL, Henry MA, Granholm AC, Hoffer BJ, et al. 6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor. Exp Brain Res. 1996; 111(1):1-7. .
37. Signorini S, Liao YJ, Duncan SA, Jan LY, Stoffel M. Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled, inwardly rectifying K+ channel GIRK2. Proc Natl Acad Sci U S A. 1997; 94(3):923-7. Epub 1997/02/04.
38. Reyes S, Fu Y, Double K, Thompson L, Kirik D, Paxinos G, et al. GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J Comp Neurol. 2012; 520(12):2591-607. doi: 10.1002/cne.23051 .
39. Polanski W, Enzensperger C, Reichmann H, Gille G. The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J Neurochem. 2010; 113(6):1659-75. doi: 10.1111/j.1471-4159.2010.06725.x .
40. Zhang C, Steiner JP, Hamilton GS, Hicks TP, Poulter MO. Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment. J Neurosci. 2001; 21(15): RC156. .
41. Levites Y, Weinreb O, Maor G, Youdim MB, Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-Tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 2001; 78(5):1073-82. Epub 2001/09/13. .
42. Hamrick SE, McQuillen PS, Jiang X, Mu D, Madan A, Ferriero DM. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci Lett. 2005; 379(2):96-100. Epub 2005/04/13. doi: S0304-3940(05)00009-1 [pii] doi: 10.1016/j.neulet.2004.12.080 .
43. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, et al. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21 (waf1/cip1), and erythropoietin. J Neurosci. 1999; 19(22):9821-30. Epub 1999/11/13. .
44. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar-Am O, Youdim MB. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience. 2011; 189:345-58. Epub 2011/05/17. doi: 10.1016/j.neuroscience.2011.03.040S0306-4522(11)00322-8 [pii]. .
45. Hurn PD, Koehler RC, Blizzard KK, Traystman RJ. Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. Stroke. 1995; 26(4):688-94; discussion 94-5. Epub 1995/04/01. .
46. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2009; 23(11):3766-79. doi: 10.1096/fj.09-130047 .
47. Fall CP, Bennett JP Jr. Characterization and time course of MPP+-induced apoptosis in human SHSY5Y neuroblastoma cells. J Neurosci Res. 1999; 55(5):620-8. .
48. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007; 447(7148):1081-6. Epub 2007/06/15. doi: nature05865 [pii] doi: 10.1038/nature05865 .
49. Chen T, Yang YF, Luo P, Liu W, Dai SH, Zheng XR, et al. Homer1 knockdown protects dopamine neurons through regulating calcium homeostasis in an in vitro model of Parkinson's disease. Cell Signal. 2013; 25(12):2863-70. Epub 2013/09/17. doi: 10.1016/j.cellsig.2013.09.004S0898-6568(13)00279-9 [pii]. .
50. Munoz P, Humeres A, Elgueta C, Kirkwood A, Hidalgo C, Nunez MT. Iron mediates N-methyl-D-Aspartate receptor-dependent stimulation of calcium-induced pathways and hippocampal synaptic plasticity. The Journal of biological chemistry. 2011; 286(15):13382-92. Epub 2011/02/08. doi: 10.1074/jbc. M110.213785
51. Sanmartin CD, Paula-Lima AC, Garcia A, Barattini P, Hartel S, Nunez MT, et al. Ryanodine receptormediated Ca(2+) release underlies iron-induced mitochondrial fission and stimulates mitochondrial Ca (2+) uptake in primary hippocampal neurons. Front Mol Neurosci. 2014; 7:13. Epub 2014/03/22. doi: 10.3389/fnmol.2014.00013